CRF1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia

Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[( 1 S)-2-cyclopropyl- 1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-l,3-thiazol-2-amine (Formula 1), or a pharmaceutically...

Full description

Saved in:
Bibliographic Details
Main Authors PARKS, Stacy, NGWENYA-JONES, Ayanda, ZHANG, Xiaoping, CHARLIER, Anne, MEHTON, Gurvinder Singh, SAYERS, Brian, IYOHA, Kingsley, COSTA, Christina Marie, VICKERY, Anthony D, LOEWEN, Gordon Raphael, CHAN, Jean L, TAYLOR, Graeme, DOWNING, Kristie M, GIRI, Nagdeep, STIRN, Scott, FARBER, Robert H
Format Patent
LanguageEnglish
Published 29.07.2021
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[( 1 S)-2-cyclopropyl- 1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-l,3-thiazol-2-amine (Formula 1), or a pharmaceutically acceptable salt thereof. Further provided are pharmaceutical formulations and solid forms of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(lS)-2-cyclopropyl-l-(3-fluoro-4-methylphenyl)ethyl]-5-mcthyl-N -prop-2 -ynyl-l,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, and their use in the treatment of congenital adrenal hyperplasia (CAH).
Bibliography:Application Number: AU20190393256